Background: Abdominal aortic aneurysm (AAA), a common disease involving the segmental
expansion and rupture of the aorta, has a high mortality rate. Therapeutic options for AAA are
currently limited to surgical repair to prevent catastrophic rupture. Non-surgical approaches, particularly
pharmacotherapy, are lacking for the treatment of AAA.
Objective: We review both basic and clinical studies and discuss the current challenges to developing
medical therapy that reduces AAA progression.
Results: Studies using animal models of AAA progression and human AAA explant cultures have
identified several potential targets for preventing AAA growth. However, no clinical studies have
convincingly confirmed the efficacy of any pharmacologic treatment against the growth of AAA.
Thus, there is as yet no strong recommendation regarding pharmacotherapy to reduce the risk of AAA
progression and rupture.
Conclusion: This review identifies concerns that need to be addressed for the field to progress and
discusses the challenges that must be overcome in order to develop effective pharmacotherapy to reduce
AAA progression in the future.